- Home
- CFLT vs RGC Comparison
CFLT vs RGC Comparison
Compare CFLT & RGC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CFLT
- RGC
- Stock Information
- Founded
- CFLT 2014
- RGC 2014
- Country
- CFLT United States
- RGC Hong Kong
- Employees
- CFLT N/A
- RGC N/A
- Industry
- CFLT EDP Services
- RGC Medicinal Chemicals and Botanical Products
- Sector
- CFLT Technology
- RGC Health Care
- Exchange
- CFLT Nasdaq
- RGC Nasdaq
- Market Cap
- CFLT 6.9B
- RGC 6.6B
- IPO Year
- CFLT 2021
- RGC 2021
- Fundamental
- Price
- CFLT $20.95
- RGC $19.70
- Analyst Decision
- CFLT Buy
- RGC
- Analyst Count
- CFLT 31
- RGC 0
- Target Price
- CFLT $28.97
- RGC N/A
- AVG Volume (30 Days)
- CFLT 6.0M
- RGC 228.8K
- Earning Date
- CFLT 10-27-2025
- RGC 10-24-2025
- Dividend Yield
- CFLT N/A
- RGC N/A
- EPS Growth
- CFLT N/A
- RGC N/A
- EPS
- CFLT N/A
- RGC N/A
- Revenue
- CFLT $1,064,824,000.00
- RGC N/A
- Revenue This Year
- CFLT $21.83
- RGC N/A
- Revenue Next Year
- CFLT $16.44
- RGC N/A
- P/E Ratio
- CFLT N/A
- RGC N/A
- Revenue Growth
- CFLT 23.02
- RGC N/A
- 52 Week Low
- CFLT $15.64
- RGC $0.09
- 52 Week High
- CFLT $37.90
- RGC $83.60
- Technical
- Relative Strength Index (RSI)
- CFLT 60.20
- RGC 74.17
- Support Level
- CFLT $19.28
- RGC $15.29
- Resistance Level
- CFLT $21.49
- RGC $16.39
- Average True Range (ATR)
- CFLT 0.84
- RGC 1.15
- MACD
- CFLT 0.15
- RGC 0.38
- Stochastic Oscillator
- CFLT 83.16
- RGC 76.81
About CFLT Confluent Inc.
Confluent Inc provides a data streaming platform that enables customers to connect their applications, systems, and data layers and can be deployed as a fully managed cloud-native software-as-a-service (SaaS) offering. Its products include Confluent Cloud, a self-managed software offering, Confluent Platform, a managed service offering where the raw data resides inside a customer's cloud environment, and WarpStream, among others. Confluent also offers professional services and education services. The company generates revenue from the sale of subscriptions and services. Geographically, it generates a majority of its revenue from its business in the United States and the rest from International markets.
About RGC Regencell Bioscience Holdings Limited
Regencell Bioscience Holdings Ltd is a bioscience company focusing on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degenerations, specifically ADHD and ASD, and infectious diseases affecting people's immune systems.